|1.||Hart, Charles P: 12 articles (07/2015 - 09/2010)|
|2.||Sun, Jessica D: 7 articles (07/2015 - 09/2010)|
|3.||Liu, Qian: 6 articles (01/2015 - 09/2010)|
|4.||Kroll, Stew: 5 articles (05/2015 - 01/2011)|
|5.||Matteucci, Mark D: 5 articles (01/2015 - 02/2012)|
|6.||Wang, Yan: 5 articles (01/2015 - 02/2012)|
|7.||Ahluwalia, Dharmendra: 5 articles (01/2015 - 02/2012)|
|8.||Wang, Jingli: 4 articles (10/2015 - 02/2012)|
|9.||Meng, Fanying: 4 articles (01/2015 - 03/2012)|
|10.||Gillies, Robert J: 4 articles (01/2015 - 09/2012)|
02/01/2012 - "Tumor-bearing animals breathing 95% O(2) exhibited attenuated TH-302 efficacy, with whereas those breathing 10% O(2) exhibited enhanced TH-302 efficacy, both compared with air (21% O(2)) breathing. "
07/01/2015 - "TH-302 selectively targets hypoxic tumor regions, where it is converted into a cytotoxic agent. "
01/01/2015 - "TH-302 cytotoxicity is greatly enhanced by Chk1 inhibition in p53-deficient but not in p53-proficient human cancer cell lines. "
09/01/2012 - "These results suggest that changes in tumor permeability and/or perfusion may be an early imaging biomarker for response to TH-302 therapy."
09/01/2012 - "No changes were observed in DW-MRI following treatment with TH-302, which may indicate that this technique is not sensitive enough to detect changes in small hypoxic fractions of the tumor targeted by TH-302. "
09/02/2010 - "Our data support that hypoxia-activated treatment with TH-302 provides a potential new treatment option for MM."
10/01/2015 - "Taken together, our study identifies POR as a potential predictive biomarker of HAP sensitivity that should be explored during the clinical development of SN30000, TH-302, and other hypoxia-directed agents."
05/01/2011 - "Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies."
10/01/2015 - "Knockdown or genetic knockout of POR reduced SN30000 reductive metabolism and clonogenic cell death and similarly reduced sensitivity to TH-302 under hypoxia. "
07/01/2015 - "TH-302 decreases the HF in both models, consistent with its hypoxia-targeting mechanism of action. "
|3.||Sarcoma (Soft Tissue Sarcoma)
06/30/2015 - "The combination of TH-302, VEGF-A inhibition, and RT is highly effective in preclinical models of sarcoma and is associated with increased DNA damage and apoptosis in endothelial cells and decreased HIF-1α activity."
10/10/2014 - "This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free survival (PFS), response rate, overall survival, safety, and tolerability. "
11/01/2014 - "TH-302 shows antitumor activity in combination with doxorubicin in advanced soft-tissue sarcoma. "
10/10/2014 - "Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma."
01/01/2011 - "The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft tissue sarcoma. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2014 - "TH-302 is a HAP that is currently being evaluated in a Phase III clinical trial in pancreatic cancer. "
01/01/2014 - "Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer."
10/01/2015 - "[TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment]."
09/01/2012 - "TH-302, a hypoxia-activated anticancer prodrug, was evaluated for antitumor activity and changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in a mouse model of pancreatic cancer. "
05/01/2015 - "This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. "
09/01/2013 - "Recently, we showed that hypoxia is a critical microenvironmental factor in multiple myeloma, and that the hypoxia-activated prodrug TH-302 selectively targets hypoxic multiple myeloma cells and improves multiple disease parameters in vivo. "
09/02/2010 - "Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug."
09/01/2013 - "In conclusion, our studies provide a rationale for clinical evaluation of the combination of TH-302 and bortezomib in patients with multiple myeloma."
09/01/2013 - "First, we show that TH-302 and bortezomib synergistically induce apoptosis in multiple myeloma cell lines in vitro. "
07/01/2015 - "Correction: Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro."
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Pyruvic Acid (Pyruvate)
|6.||Proteasome Endopeptidase Complex (Proteasome)
|7.||isophosphamide mustard (IPAM)
|8.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)